Gemphire Therapeutics shares rose after the company revealed positive results from a pre-clinical study of gemcabene that showed proof of concept efficacy in a well-established animal model of nonalcoholic steatohepatitis (NASH).

Gemphire plans to initiate clinical development of gemcabene in NASH/nonalcoholic fatty liver disease with a Phase 2 trial in 2017. There are currently no treatments for NAFLD and NASH approved by the Food and Drug Administration. The complete NASH preclinical results will be submitted for publication in 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with’s FREE daily email newsletter.